She didn’t improve. She relocated.

Hey Reader, Dr Karl here.

She didn’t improve. She relocated.

This is the sentence I most want you to take from all of this.

Her HOMA-IR went from 2.6 to 0.8. The easy way to describe that is “she improved.” It is also the wrong way, and the difference matters more than almost anything else I could tell you.

She did not get better inside a category. She changed which category she is in.

She left the country. She was living in the insulin resistant population, and she is now living in the non insulin resistant population. Different rules, different patterns, different future.

That is not a shade of improvement. That is a border crossing.

And once you see it that way, the reference range starts to look like what it is: a fence around one number that tells you nothing about which country you are standing in. A fasting insulin of 9.6 is inside the fence. It is also, unambiguously, the wrong country.

Where do the plots come from that let me see this? Clients come in, they all run the same panel, which has grown over the years. The results go into one long spreadsheet. Each person is a row. Each lab is a column. Then I plot, and I split by HOMA-IR.

Raw data in, pattern out. From individual lab values to meaningful clinical patterns. That phrase is doing real work: meaningful is the opposite of in range.